


# Explore toxicities associated with compounds and targets


## Cortellis Drug Discovery Intelligence

There are 3 ways of exploring toxicity data in the platform:

- Via **Experimental pharmacology** for toxicities reported in preclinical models
- Via **Clinical studies** for case studies where adverse events have been reported in humans
- Via **Biomarkers** that can predict or monitor the toxic effects of your drugs of interest – Requires a separate subscription to access Biomarkers Module

 \*In addition, subscribers to **OFF-X** can access further drug safety data by clicking on **Safety Alerts** in **Drug & Biologics** and **Genes & Targets** records.

To start with, **Quick Search** for your drug / drug class / target of interest. Eg MoA = **PARP inhibitors**.



From the **All Related Content** page navigate to the area of interest.

All results for "NAD+ ADP-Ribosyltransferase (poly(ADP-ribose) Polymerase; PARP) Inhibit..."


<p>2029 Drugs &amp; Biologics</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>58 Genes &amp; Targets</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>113 Organic Synthesis</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>
<p>16260 Experimental Pharmacology</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>1862 Experimental Models</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>9437 Pharmacokinetics</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>
<p>8649 Clinical Studies</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>277 Organizations</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>19111 Literature</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>
<p>1248 Patents</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>20 Disease Briefings</p> <p><a href="#">View results</a> <a href="#">Related content</a></p>	<p>4781 Biomarkers</p> <p><b>13141 Uses</b></p> <p><a href="#">View results</a> <a href="#">Related content</a></p>

1

2

3


1. Go to **Experimental Pharmacology** – Click on **Apply filters > Toxicity** to view the list of toxicity-related **Experimental Activities** shown in your results. **Select All** to refine your results and view the details.



Apply Filters		Search	Select all / Clear all
Experimental Activity	>		
Pharmacological Activity	>		
Target	>		
Condition	>		
<b>Toxicity</b>	<b>(15)</b> >		
Activity/Effect	>		
System	>		

- Cytotoxicity (298)
- Death (40)
- Hepatotoxicity (20)
- Neurotoxicity (18)
- Cancer, breast (9)
- Genotoxicity (6)
- Leukemia, promyelocytic acute (6)
- Nephrotoxicity (3)
- Phototoxicity (3)

2. Go to **Clinical studies** – Click on **Apply filters > Condition** and refine by **Adverse Events** and **Drug toxicities and Adverse Events**. Find details on the reported adverse events in the **Conclusions/Objective** section within the records.



Clinical Studies Record		Apply Filters	
<b>General Information</b>		Study Design	>
		Phase	>
		<b>Condition</b>	<b>(5)</b> >
		Intervention Type	>

Study Name: Neutropenic enteritis/cutaneous hyperpigmentation due to pemetrexed

Study Design: Case report

Population: Male Caucasian patient aged 77 y with malignant pleural mesothelioma

Population Number: 1

Intervention: Carboplatin, 225 mg/m2 + Pemetrexed, 500 mg/m2 1x/4 wks x 3 cycles --> [if severe abdominal pain] Pemetrexed, 420 mg/m2


Intervention Type: Drug therapy

Drugs: Carboplatin, Pemetrexed disodium

**Conclusions/Objectives: Treatment with pemetrexed resulted in neutropenic enteritis and severe cutaneous hyperpigmentation in a male Caucasian patient with malignant pleural mesothelioma**

Condition: Adverse Events, Gastroenteritis, Hyperpigmentation, skin, Mesothelioma, malignant [Show 1 more](#)

- Go to **Biomarker Uses** – Click on **Apply filters > Role** and refine by **Predicting treatment toxicity, Monitoring treatment toxicity, and Toxicity profiling**.



The screenshot shows the 'Apply Filters' sidebar on the left and the 'Biomarker Uses' table on the right. The filter 'Role' is expanded to show three selected options: 'Predicting Treatment Toxicity (317)', 'Monitoring Treatment Toxicity (76)', and 'Toxicity Profiling (70)'. The table below shows the results of these filters.

Biomarker Name	Indication	Population
<input type="checkbox"/> Glucose	<input checked="" type="checkbox"/> Tx Hypercalcemia (grade 3)	Cancer
<input type="checkbox"/> Aspartate aminotransferase	<input checked="" type="checkbox"/> Tx Aspartate aminotransferase elevation (grade 2)	Cancer
<input type="checkbox"/> Glucose	<input checked="" type="checkbox"/> Tx Hypercalcemia (grade 2)	Cancer

the **Tx** symbol in front of the **Indication** column shows which adverse event was detected by the biomarker.

The condition under the **Population** column shows the underlying condition that was being treated

For more information contact Customer Service at [LS Product Support](#)